<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357368</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00072549</org_study_id>
    <secondary_id>5K23HD078153-05</secondary_id>
    <nct_id>NCT02357368</nct_id>
  </id_info>
  <brief_title>Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk</brief_title>
  <official_title>Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lisa Haddad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort study focusing on HIV negative women. The investigators want to&#xD;
      learn how the contraceptive methods of depot medroxyprogesterone acetate (DMPA), etonogestrel&#xD;
      implant (Eng-Implant), levonorgestrel intrauterine device (Lng-IUD) and the ParaGard® T 380A&#xD;
      Intrauterine Copper Contraceptive impact the vaginal immune environment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The three proposed aims will evaluate the effect of four contraceptive methods (depot&#xD;
      medroxyprogesterone acetate (DMPA), etonogestrel implant (Eng-Implant), levonorgestrel&#xD;
      intrauterine device (Lng-IUD) and ParaGard® T 380A Intrauterine Copper Contraceptive) on: (1)&#xD;
      HIV target immune cells within the female genital mucosa; (2) markers of T-cell activation&#xD;
      and trafficking within the female genital mucosa; and (3) secreted cytokines and chemokines&#xD;
      within the female genital mucosa.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">October 23, 2019</completion_date>
  <primary_completion_date type="Actual">October 23, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of HIV Target Immune Cells Within Female Genital Mucosa and Blood</measure>
    <time_frame>Week 1, Week 17</time_frame>
    <description>Following exposure to HIV, initial infection occurs at the genital mucosa and may involve complex interactions between a number of HIV target immune cells. HIV often uses C-C Chemokine Receptor Type 5 (CCR5) for entrance into target immune cells, causing infection of the cell. The amount of CCR5 expressing macrophages is associated with HIV infection. Cluster of differentiation 4 (CD4) T Cells are targeted and infected by HIV and CD4 percentages are used to assess immune status. CD4 counts vary by individuals and generally decrease with HIV infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of CD4/Cluster of Differentiation 8 (CD8) T-Cells Within Female Genital Mucosa and Blood</measure>
    <time_frame>Week 1, Week 17</time_frame>
    <description>CD4/CD8 ratios above 1 indicate a strong immune system while lower ratios indicate a viral infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Markers of T-cell Activation and Trafficking Within the Female Genital Mucosa and Blood</measure>
    <time_frame>Week 1, Week 17</time_frame>
    <description>T cell activation correlates with HIV infection progression and this study seeks to gain better understanding of these underlying mechanisms by assessment of HIV target cells. Changes in cluster of differentiation 38 (CD38) expression are indicators of HIV disease progression with increases seen in CD38+ when a chronic HIV infection is progressing. Human leukocyte antigen-antigen D related (HLA-DR)+ expression appears to be involved in HIV proliferation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration Levels of Secreted Cytokines and Chemokines Within the Female Genital Mucosa and Blood</measure>
    <time_frame>Week 1, Week 17</time_frame>
    <description>The concentration levels of interleukin 1 (IL-1) family cytokines and interferon gamma-induced protein 10 (IP-10) chemokines were determined using multiplex Luminex® assays combined with a customized multi-analytical panel of 22 human cytokines and chemokines. IL-1 and IP-10 have been found to influence recruitment of HIV target cells to the female reproductive tract and this study is examining changes in IL-1 and PI-10 to gain further understanding of these mechanisms.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>HIV</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Depot medroxyprogesterone acetate (DMPA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DMPA will be administered every 12 weeks at 150 mg by intramuscular (IM) injection at week 3 of study enrollment and repeated at week 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etonogestrel implant (Eng-Implant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A standard Nexplanon rod Implant will be placed at study week 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levonorgestrel intrauterine device (Lng-IUD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A standard Mirena IUD will be placed at study week 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ParaGard® T 380A Intrauterine Copper Contraceptive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A standard ParaGuard IUD will be placed at study week 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depot medroxyprogesterone acetate (DMPA)</intervention_name>
    <description>DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.</description>
    <arm_group_label>Depot medroxyprogesterone acetate (DMPA)</arm_group_label>
    <other_name>Depo Provera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Etonogestrel implant (Eng-Implant)</intervention_name>
    <description>A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.</description>
    <arm_group_label>Etonogestrel implant (Eng-Implant)</arm_group_label>
    <other_name>Nexplanon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Levonorgestrel intrauterine device (Lng-IUD)</intervention_name>
    <description>A standard Mirena IUD will be placed at study week 3 by a trained clinician.</description>
    <arm_group_label>Levonorgestrel intrauterine device (Lng-IUD)</arm_group_label>
    <other_name>Mirena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ParaGard® T 380A Intrauterine Copper Contraceptive</intervention_name>
    <description>A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.</description>
    <arm_group_label>ParaGard® T 380A Intrauterine Copper Contraceptive</arm_group_label>
    <other_name>ParaGuard</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Age 18-45 years&#xD;
&#xD;
          -  Normal menses (22-35 day intervals) for at least 3 cycles&#xD;
&#xD;
          -  Intact uterus and cervix&#xD;
&#xD;
          -  Interested in to DMPA, Eng-Implant or Lng-IUD or ParaGuard&#xD;
&#xD;
          -  Willing to delay initiation of hormonal contraception for up to 1 month&#xD;
&#xD;
          -  Willing to use condoms or abstain from sexual intercourse for at least 48 hours before&#xD;
             each genital tract sampling (condoms will be made available)&#xD;
&#xD;
          -  Able and willing to provide informed consent, and undergo serial blood and&#xD;
             cervicovaginal lavage (CVL) sampling&#xD;
&#xD;
          -  Negative HIV screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant within the last 3 months&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  History of loop electrosurgical excision procedure, conization, or cryosurgery within&#xD;
             the past year&#xD;
&#xD;
          -  Use of hormonal contraception or IUD in the past 6 months&#xD;
&#xD;
          -  Known history of medical condition that would interfere with the conduct of the study&#xD;
&#xD;
          -  Symptomatic vaginal infection or genital ulcer disease at screening&#xD;
&#xD;
          -  Taking medications that interact with selected contraceptive&#xD;
&#xD;
          -  Contraindications to selected contraceptive per the Centers for Disease Control and&#xD;
             Prevention (CDC) medical eligibility criteria or judgment of clinician&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Haddad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Center of the Grady Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Clinical Research Network</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>February 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <results_first_submitted>October 23, 2020</results_first_submitted>
  <results_first_submitted_qc>October 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 18, 2020</results_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Lisa Haddad</investigator_full_name>
    <investigator_title>Asscoiate Professor</investigator_title>
  </responsible_party>
  <keyword>HIV-negative</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Copper</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02357368/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02357368/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled between February 2015 and follow up was completed on October 23, 2019. Participants were recruited from the Grady Family Planning Clinic within Grady Memorial Hospital, the Emory Clinic, and the Ponce de Leon Center of the Grady Health System, in Atlanta, Georgia.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Depot Medroxyprogesterone Acetate (DMPA)</title>
          <description>Participants receiving depot medroxyprogesterone acetate (DMPA) administered every 12 weeks at the standard dose of 150 mg intramuscular injection, beginning from Week 3 of study enrollment and repeated at Week 15</description>
        </group>
        <group group_id="P2">
          <title>Etonogestrel Impant (Eng-Implant)</title>
          <description>Participants receiving a standard nexplanon rod implant that was placed at study Week 3 by a trained clinician</description>
        </group>
        <group group_id="P3">
          <title>Levonorgestrel Intrauterine Device (Lng-IUD)</title>
          <description>Participants receiving a standard Mirena intrauterine device (IUD) that was placed at study Week 3 by a trained clinician</description>
        </group>
        <group group_id="P4">
          <title>ParaGard® T 380A Intrauterine Copper Contraceptive</title>
          <description>Participants receiving a standard ParaGuard IUD that was placed at study week 3 by a trained clinician</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Depot Medroxyprogesterone Acetate (DMPA)</title>
          <description>Participants receiving DMPA administered every 12 weeks at the standard dose of 150 mg intramuscular injection, beginning from Week 3 of study enrollment and repeated at Week 15</description>
        </group>
        <group group_id="B2">
          <title>Etonogestrel Impant (Eng-Implant)</title>
          <description>Participants receiving a standard nexplanon rod implant that was placed at study Week 3 by a trained clinician</description>
        </group>
        <group group_id="B3">
          <title>Levonorgestrel Intrauterine Device (Lng-IUD)</title>
          <description>Participants receiving a standard Mirena IUD that was placed at study Week 3 by a trained clinician</description>
        </group>
        <group group_id="B4">
          <title>ParaGard® T 380A Intrauterine Copper Contraceptive</title>
          <description>Participants receiving a standard ParaGuard IUD that was placed at study week 3 by a trained clinician</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>Continuous age is not available for the ParaGard® T 380A Intrauterine Copper Contraceptive study arm. This group was added late in the study and the study procedures differed slightly from the initial three study arms.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.1" spread="7.8"/>
                    <measurement group_id="B2" value="27.7" spread="7.2"/>
                    <measurement group_id="B3" value="31.1" spread="7.9"/>
                    <measurement group_id="B5" value="31.0" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Ethnicity is not available for the ParaGard® T 380A Intrauterine Copper Contraceptive study arm. This group was added late in the study and the study procedures differed slightly from the initial three study arms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Race is not available for the ParaGard® T 380A Intrauterine Copper Contraceptive study arm. This group was added late in the study and the study procedures differed slightly from the initial three study arms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of HIV Target Immune Cells Within Female Genital Mucosa and Blood</title>
        <description>Following exposure to HIV, initial infection occurs at the genital mucosa and may involve complex interactions between a number of HIV target immune cells. HIV often uses C-C Chemokine Receptor Type 5 (CCR5) for entrance into target immune cells, causing infection of the cell. The amount of CCR5 expressing macrophages is associated with HIV infection. Cluster of differentiation 4 (CD4) T Cells are targeted and infected by HIV and CD4 percentages are used to assess immune status. CD4 counts vary by individuals and generally decrease with HIV infection.</description>
        <time_frame>Week 1, Week 17</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Depot Medroxyprogesterone Acetate (DMPA)</title>
            <description>Participants receiving DMPA administered every 12 weeks at the standard dose of 150 mg intramuscular injection, beginning from Week 3 of study enrollment and repeated at Week 15</description>
          </group>
          <group group_id="O2">
            <title>Etonogestrel Impant (Eng-Implant)</title>
            <description>Participants receiving a standard nexplanon rod implant that was placed at study Week 3 by a trained clinician</description>
          </group>
          <group group_id="O3">
            <title>Levonorgestrel Intrauterine Device (Lng-IUD)</title>
            <description>Participants receiving a standard Mirena IUD that was placed at study Week 3 by a trained clinician</description>
          </group>
          <group group_id="O4">
            <title>ParaGard® T 380A Intrauterine Copper Contraceptive</title>
            <description>Participants receiving a standard ParaGuard IUD that was placed at study week 3 by a trained clinician</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of HIV Target Immune Cells Within Female Genital Mucosa and Blood</title>
          <description>Following exposure to HIV, initial infection occurs at the genital mucosa and may involve complex interactions between a number of HIV target immune cells. HIV often uses C-C Chemokine Receptor Type 5 (CCR5) for entrance into target immune cells, causing infection of the cell. The amount of CCR5 expressing macrophages is associated with HIV infection. Cluster of differentiation 4 (CD4) T Cells are targeted and infected by HIV and CD4 percentages are used to assess immune status. CD4 counts vary by individuals and generally decrease with HIV infection.</description>
          <units>percentage of HIV target immune cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CCR5+ CD4 T-cells Cervicovaginal Lavage (CVL) Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" spread="22.3"/>
                    <measurement group_id="O2" value="22.8" spread="20.5"/>
                    <measurement group_id="O3" value="16.9" spread="16.4"/>
                    <measurement group_id="O4" value="22.4" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCR5+ CD4 T-cells CVL Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" spread="27.6"/>
                    <measurement group_id="O2" value="32.2" spread="21.1"/>
                    <measurement group_id="O3" value="23.3" spread="20.6"/>
                    <measurement group_id="O4" value="15.3" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCR5+ CD4 T-cells Peripheral Blood Mononuclear Cell (PBMC) Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.9"/>
                    <measurement group_id="O2" value="3.9" spread="2.5"/>
                    <measurement group_id="O3" value="2.9" spread="1.7"/>
                    <measurement group_id="O4" value="8.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCR5+ CD4 T-cells PBMC Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="3.5"/>
                    <measurement group_id="O2" value="4.2" spread="2.7"/>
                    <measurement group_id="O3" value="2.6" spread="1.4"/>
                    <measurement group_id="O4" value="7.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4% CVL Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2" spread="17.5"/>
                    <measurement group_id="O2" value="48.7" spread="16.7"/>
                    <measurement group_id="O3" value="54.0" spread="20.5"/>
                    <measurement group_id="O4" value="63.4" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4% CVL Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="18.2"/>
                    <measurement group_id="O2" value="47.0" spread="16.3"/>
                    <measurement group_id="O3" value="48.8" spread="23.5"/>
                    <measurement group_id="O4" value="47.5" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4% PBMC Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6" spread="10.6"/>
                    <measurement group_id="O2" value="67.4" spread="8.0"/>
                    <measurement group_id="O3" value="65.7" spread="9.4"/>
                    <measurement group_id="O4" value="73.3" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4% PBMC Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9" spread="10.1"/>
                    <measurement group_id="O2" value="67.5" spread="9.4"/>
                    <measurement group_id="O3" value="63.4" spread="10.8"/>
                    <measurement group_id="O4" value="71.1" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of CD4/Cluster of Differentiation 8 (CD8) T-Cells Within Female Genital Mucosa and Blood</title>
        <description>CD4/CD8 ratios above 1 indicate a strong immune system while lower ratios indicate a viral infection.</description>
        <time_frame>Week 1, Week 17</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Depot Medroxyprogesterone Acetate (DMPA)</title>
            <description>Participants receiving DMPA administered every 12 weeks at the standard dose of 150 mg intramuscular injection, beginning from Week 3 of study enrollment and repeated at Week 15</description>
          </group>
          <group group_id="O2">
            <title>Etonogestrel Impant (Eng-Implant)</title>
            <description>Participants receiving a standard nexplanon rod implant that was placed at study Week 3 by a trained clinician</description>
          </group>
          <group group_id="O3">
            <title>Levonorgestrel Intrauterine Device (Lng-IUD)</title>
            <description>Participants receiving a standard Mirena IUD that was placed at study Week 3 by a trained clinician</description>
          </group>
          <group group_id="O4">
            <title>ParaGard® T 380A Intrauterine Copper Contraceptive</title>
            <description>Participants receiving a standard ParaGuard IUD that was placed at study week 3 by a trained clinician</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of CD4/Cluster of Differentiation 8 (CD8) T-Cells Within Female Genital Mucosa and Blood</title>
          <description>CD4/CD8 ratios above 1 indicate a strong immune system while lower ratios indicate a viral infection.</description>
          <units>CD4/CD8</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4/CD8 Ratio Cervicovaginal Lavage (CVL) Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.5"/>
                    <measurement group_id="O2" value="2.6" spread="1.8"/>
                    <measurement group_id="O3" value="2.9" spread="3.0"/>
                    <measurement group_id="O4" value="3.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4/CD8 Ratio CVL Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="2.7"/>
                    <measurement group_id="O2" value="2.3" spread="2.0"/>
                    <measurement group_id="O3" value="2.3" spread="2.1"/>
                    <measurement group_id="O4" value="4.9" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4/CD8 Ratio Peripheral Blood Mononuclear Cell (PBMC) Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="8.8"/>
                    <measurement group_id="O2" value="3.1" spread="1.7"/>
                    <measurement group_id="O3" value="2.9" spread="1.5"/>
                    <measurement group_id="O4" value="4.7" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4/CD8 Ratio PBMC Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.3"/>
                    <measurement group_id="O2" value="3.3" spread="2.5"/>
                    <measurement group_id="O3" value="2.5" spread="1.2"/>
                    <measurement group_id="O4" value="5.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Markers of T-cell Activation and Trafficking Within the Female Genital Mucosa and Blood</title>
        <description>T cell activation correlates with HIV infection progression and this study seeks to gain better understanding of these underlying mechanisms by assessment of HIV target cells. Changes in cluster of differentiation 38 (CD38) expression are indicators of HIV disease progression with increases seen in CD38+ when a chronic HIV infection is progressing. Human leukocyte antigen-antigen D related (HLA-DR)+ expression appears to be involved in HIV proliferation.</description>
        <time_frame>Week 1, Week 17</time_frame>
        <population>This analysis includes participants with samples that were able to be analyzed. Missing values are due to the inability to quantify the outcomes due to low cell counts when looking at the percent + of few cells for those samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Depot Medroxyprogesterone Acetate (DMPA)</title>
            <description>Participants receiving DMPA administered every 12 weeks at the standard dose of 150 mg intramuscular injection, beginning from Week 3 of study enrollment and repeated at Week 15</description>
          </group>
          <group group_id="O2">
            <title>Etonogestrel Impant (Eng-Implant)</title>
            <description>Participants receiving a standard nexplanon rod implant that was placed at study Week 3 by a trained clinician</description>
          </group>
          <group group_id="O3">
            <title>Levonorgestrel Intrauterine Device (Lng-IUD)</title>
            <description>Participants receiving a standard Mirena IUD that was placed at study Week 3 by a trained clinician</description>
          </group>
          <group group_id="O4">
            <title>ParaGard® T 380A Intrauterine Copper Contraceptive</title>
            <description>Participants receiving a standard ParaGuard IUD that was placed at study week 3 by a trained clinician</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Markers of T-cell Activation and Trafficking Within the Female Genital Mucosa and Blood</title>
          <description>T cell activation correlates with HIV infection progression and this study seeks to gain better understanding of these underlying mechanisms by assessment of HIV target cells. Changes in cluster of differentiation 38 (CD38) expression are indicators of HIV disease progression with increases seen in CD38+ when a chronic HIV infection is progressing. Human leukocyte antigen-antigen D related (HLA-DR)+ expression appears to be involved in HIV proliferation.</description>
          <population>This analysis includes participants with samples that were able to be analyzed. Missing values are due to the inability to quantify the outcomes due to low cell counts when looking at the percent + of few cells for those samples.</population>
          <units>percentage of T cell activation markers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD38+ CD4 T-cells Cervicovaginal Lavage (CVL) Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="18.4"/>
                    <measurement group_id="O2" value="36.9" spread="17.6"/>
                    <measurement group_id="O3" value="32.6" spread="11.6"/>
                    <measurement group_id="O4" value="23.2" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD38+ CD4 T-cells CVL Week 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" spread="18.6"/>
                    <measurement group_id="O2" value="41.7" spread="14.8"/>
                    <measurement group_id="O3" value="44.0" spread="15.4"/>
                    <measurement group_id="O4" value="45.5" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD38+ CD4 T-cells Peripheral Blood Mononuclear Cell (PBMC) Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" spread="7.3"/>
                    <measurement group_id="O2" value="17.6" spread="10.1"/>
                    <measurement group_id="O3" value="17.0" spread="9.0"/>
                    <measurement group_id="O4" value="25.2" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD38+ CD4 T-cells PBMC Week 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="6.9"/>
                    <measurement group_id="O2" value="17.6" spread="8.4"/>
                    <measurement group_id="O3" value="17.2" spread="7.0"/>
                    <measurement group_id="O4" value="36.3" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HLA-DR+ CD4 T-cells CVL Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="18.3"/>
                    <measurement group_id="O2" value="26.9" spread="22.8"/>
                    <measurement group_id="O3" value="15.4" spread="10.4"/>
                    <measurement group_id="O4" value="8.7" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HLA-DR+ CD4 T-cells CVL Week 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="16.6"/>
                    <measurement group_id="O2" value="17.8" spread="13.8"/>
                    <measurement group_id="O3" value="11.4" spread="6.9"/>
                    <measurement group_id="O4" value="21.1" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HLA-DR+ CD4 T-cells PBMC Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="3.4"/>
                    <measurement group_id="O2" value="3.0" spread="1.5"/>
                    <measurement group_id="O3" value="3.3" spread="2.1"/>
                    <measurement group_id="O4" value="3.4" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HLA-DR+ CD4 T-cells PBMC Week 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="2.9"/>
                    <measurement group_id="O2" value="2.3" spread="0.9"/>
                    <measurement group_id="O3" value="3.6" spread="6.2"/>
                    <measurement group_id="O4" value="2.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD38+ Target (CCR5+ CD4+) T cells CVL Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="20.6"/>
                    <measurement group_id="O2" value="64.5" spread="26.9"/>
                    <measurement group_id="O3" value="66.2" spread="18.4"/>
                    <measurement group_id="O4" value="12.7" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD38+ Target (CCR5+ CD4+) T cells CVL Week 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" spread="20.7"/>
                    <measurement group_id="O2" value="61.6" spread="14.7"/>
                    <measurement group_id="O3" value="70.8" spread="18.9"/>
                    <measurement group_id="O4" value="42.4" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD38+ Target (CCR5+ CD4+) T cells PBMC Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="8.6"/>
                    <measurement group_id="O2" value="26.0" spread="12.8"/>
                    <measurement group_id="O3" value="28.2" spread="10.6"/>
                    <measurement group_id="O4" value="18.6" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD38+ Target (CCR5+ CD4+) T cells PBMC Week 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" spread="9.2"/>
                    <measurement group_id="O2" value="29.6" spread="12.1"/>
                    <measurement group_id="O3" value="31.7" spread="9.7"/>
                    <measurement group_id="O4" value="30.9" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HLA-DR+ Target (CCR5+ CD4+) T cells CVL Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" spread="21.6"/>
                    <measurement group_id="O2" value="41.3" spread="24.8"/>
                    <measurement group_id="O3" value="28.2" spread="16.3"/>
                    <measurement group_id="O4" value="20.1" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HLA-DR+ Target (CCR5+ CD4+) T cells CVL Week 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" spread="17.6"/>
                    <measurement group_id="O2" value="25.5" spread="17.9"/>
                    <measurement group_id="O3" value="17.6" spread="11.9"/>
                    <measurement group_id="O4" value="26.5" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HLA-DR+ Target (CCR5+ CD4+) T cells PBMC Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" spread="10.4"/>
                    <measurement group_id="O2" value="22.6" spread="7.4"/>
                    <measurement group_id="O3" value="28.3" spread="10.1"/>
                    <measurement group_id="O4" value="16.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HLA-DR+ Target (CCR5+ CD4+) T cells PBMC Week 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="10.4"/>
                    <measurement group_id="O2" value="21.6" spread="7.6"/>
                    <measurement group_id="O3" value="25.5" spread="11.6"/>
                    <measurement group_id="O4" value="10.1" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration Levels of Secreted Cytokines and Chemokines Within the Female Genital Mucosa and Blood</title>
        <description>The concentration levels of interleukin 1 (IL-1) family cytokines and interferon gamma-induced protein 10 (IP-10) chemokines were determined using multiplex Luminex® assays combined with a customized multi-analytical panel of 22 human cytokines and chemokines. IL-1 and IP-10 have been found to influence recruitment of HIV target cells to the female reproductive tract and this study is examining changes in IL-1 and PI-10 to gain further understanding of these mechanisms.</description>
        <time_frame>Week 1, Week 17</time_frame>
        <population>The ParaGard® T 380A Intrauterine Copper Contraceptive study arm was added late in the study the study procedures differed slightly from the initial three study arms. Funding to add this study arm covered the evaluation of the clinical study activities and cellular markers and there was not funding for analysis of cytokines and chemokines.</population>
        <group_list>
          <group group_id="O1">
            <title>Depot Medroxyprogesterone Acetate (DMPA)</title>
            <description>Participants receiving DMPA administered every 12 weeks at the standard dose of 150 mg intramuscular injection, beginning from Week 3 of study enrollment and repeated at Week 15</description>
          </group>
          <group group_id="O2">
            <title>Etonogestrel Impant (Eng-Implant)</title>
            <description>Participants receiving a standard nexplanon rod implant that was placed at study Week 3 by a trained clinician</description>
          </group>
          <group group_id="O3">
            <title>Levonorgestrel Intrauterine Device (Lng-IUD)</title>
            <description>Participants receiving a standard Mirena IUD that was placed at study Week 3 by a trained clinician</description>
          </group>
          <group group_id="O4">
            <title>ParaGard® T 380A Intrauterine Copper Contraceptive</title>
            <description>Participants receiving a standard ParaGuard IUD that was placed at study week 3 by a trained clinician</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration Levels of Secreted Cytokines and Chemokines Within the Female Genital Mucosa and Blood</title>
          <description>The concentration levels of interleukin 1 (IL-1) family cytokines and interferon gamma-induced protein 10 (IP-10) chemokines were determined using multiplex Luminex® assays combined with a customized multi-analytical panel of 22 human cytokines and chemokines. IL-1 and IP-10 have been found to influence recruitment of HIV target cells to the female reproductive tract and this study is examining changes in IL-1 and PI-10 to gain further understanding of these mechanisms.</description>
          <population>The ParaGard® T 380A Intrauterine Copper Contraceptive study arm was added late in the study the study procedures differed slightly from the initial three study arms. Funding to add this study arm covered the evaluation of the clinical study activities and cellular markers and there was not funding for analysis of cytokines and chemokines.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IP-10 Cervicovaginal Lavage (CVL) Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="689.8" spread="1052.5"/>
                    <measurement group_id="O2" value="2551.1" spread="2936.2"/>
                    <measurement group_id="O3" value="1100.2" spread="1974.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10 CVL Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445.8" spread="996.1"/>
                    <measurement group_id="O2" value="2417.6" spread="3667.7"/>
                    <measurement group_id="O3" value="1241.5" spread="1088.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10 Peripheral Blood Mononuclear Cell (PBMC) Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3298.5" spread="2066.1"/>
                    <measurement group_id="O2" value="4107.3" spread="1455.4"/>
                    <measurement group_id="O3" value="204.4" spread="83.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10 PBMC Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3114.4" spread="1843.8"/>
                    <measurement group_id="O2" value="3954.3" spread="1617.0"/>
                    <measurement group_id="O3" value="209.6" spread="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1a CVL Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="752.2" spread="1616.8"/>
                    <measurement group_id="O2" value="1640.2" spread="2051.6"/>
                    <measurement group_id="O3" value="256.4" spread="413.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1a CVL Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="550.7" spread="695.8"/>
                    <measurement group_id="O2" value="2120.6" spread="2569.5"/>
                    <measurement group_id="O3" value="184.7" spread="251.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1a PBMC Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" spread="154.2"/>
                    <measurement group_id="O2" value="156.2" spread="233.2"/>
                    <measurement group_id="O3" value="54.6" spread="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1a PBMC Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" spread="118.2"/>
                    <measurement group_id="O2" value="144.1" spread="235.9"/>
                    <measurement group_id="O3" value="65.1" spread="78.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1b CVL Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" spread="50.3"/>
                    <measurement group_id="O2" value="583.4" spread="1569.9"/>
                    <measurement group_id="O3" value="43.9" spread="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1b CVL Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" spread="42.0"/>
                    <measurement group_id="O2" value="485.8" spread="971.9"/>
                    <measurement group_id="O3" value="37.1" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1b PBMC Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="11.2"/>
                    <measurement group_id="O2" value="51.4" spread="73.2"/>
                    <measurement group_id="O3" value="4.2" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1b PBMC Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="10.8"/>
                    <measurement group_id="O2" value="46.5" spread="58.1"/>
                    <measurement group_id="O3" value="4.3" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Information on adverse events was collected from the time of giving consent to participate through Study Visit 4 (Week 17).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Depot Medroxyprogesterone Acetate (DMPA)</title>
          <description>Participants receiving DMPA administered every 12 weeks at the standard dose of 150 mg intramuscular injection, beginning from Week 3 of study enrollment and repeated at Week 15</description>
        </group>
        <group group_id="E2">
          <title>Etonogestrel Impant (Eng-Implant)</title>
          <description>Participants receiving a standard nexplanon rod implant that was placed at study Week 3 by a trained clinician</description>
        </group>
        <group group_id="E3">
          <title>Levonorgestrel Intrauterine Device (Lng-IUD)</title>
          <description>Participants receiving a standard Mirena IUD that was placed at study Week 3 by a trained clinician</description>
        </group>
        <group group_id="E4">
          <title>ParaGard® T 380A Intrauterine Copper Contraceptive</title>
          <description>Participants receiving a standard ParaGuard IUD that was placed at study week 3 by a trained clinician</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Extended spotting 7 days before start of menstrual cycle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Extended menstrual bleeding with blood clots</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Heavy irregular menstrual bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa Haddad, MD</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1385</phone>
      <email>lisa.haddad@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

